In vivo characterization of A-192411: a novel fungicidal lipopeptide (II).
The ability of the novel antifungal cyclic hexalipopetide A-192411 to treat fungal infections in rodents is presented. Efficacy was demonstrated against Candida albicans as both prolonged survival of systemically infected mice and clearance of viable yeasts from kidneys. The efficacy of A-192411, administered intraperitoneally, was equivalent to amphotercin B at a 4-fold lower dose by weight in the systemic candidiasis models in mice, while the efficacy of A-192441 administered intravenously was equivalent to amphotercin B by weight in the Candida pyelonephritis model in rats. A-192411 also slightly prolonged the survival of immunocompromised mice infected systemically with Aspergillus fumigatus.
Meulbroek
Jonathan A
JA
Infectious Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA. ybennani@athersys.com
Nilius
Angela M
AM
Li
Qun
Q
Wang
Weibo
W
Hasvold
Lisa
L
Steiner
Beth
B
Dickman
Daniel A
DA
Ding
Hong
H
Frost
David
D
Goldman
Robert C
RC
Lartey
Paul
P
Plattner
Jacob J
JJ
Bennani
Youssef L
YL
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology; D001232:Aspergillus fumigatus; D002176:Candida albicans; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D025141:Drug Resistance, Fungal; D016867:Immunocompromised Host; D007668:Kidney / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D051381:Rats; D016019:Survival Analysis
C476327:A-192411; D000935:Antifungal Agents; D009842:Oligopeptides; D000666:Amphotericin B